Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
137 shown of 6,269 total abstracts
  1. Abstract 17792026-06-04 · 21:15 CT · S406
    DESTINY-Breast-615: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    T. Mok, S. Tolaney, M. Krop, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 17872026-06-02 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-627 study)
    H. Rugo, T. Mok, G. Curigliano, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 18112026-06-05 · 21:30 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    L. Paz-Ares, S. Modi · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 18462026-06-03 · 18:30 CT · S406
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    H. Borghaei, L. Paz-Ares, S. Peters, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 64552026-06-05 · 20:45 CT · S406
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-175
    P. Schmid, C. Saura, R. Herbst, et al. · Institut Gustave Roussy
    Education SessionGynecologic Cancer📄🖼️
  6. Abstract 95362026-06-01 · 18:00 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    S. Antonia, S. Tolaney, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 91192026-06-02 · 20:30 CT · S406
    IMpower-569: Tecentriq (atezolizumab) 2L in NSCLC
    N. Rizvi, T. Mok, M.C. Garassino, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 98532026-06-05 · 18:00 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    F. Andre, S. Tolaney, S. Peters, et al. · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 92972026-06-02 · 18:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-211 study)
    S. Peters, L. Paz-Ares, G. Curigliano · Chinese University of Hong Kong
    Education SessionLung Cancer—Small Cell📄🖼️
  10. Abstract 90722026-06-05 · 13:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    J. Brahmer, N. Rizvi, M. Krop, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 57322026-06-05 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-362
    H. Borghaei, F. Andre · Mayo Clinic
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  12. Abstract 16162026-06-03 · 16:15 CT · S406
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-366
    J. Cortes, S. Peters, A. Spira, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 15322026-06-04 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-21 study)
    S. Peters, H. Rugo, F. Andre · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 91412026-06-05 · 20:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-942
    S. Peters, R. Herbst, A. Spira, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 52012026-06-02 · 21:30 CT · Arie Crown Theater
    OlympiA-446: Lynparza (olaparib) 1L in prostate
    S. Peters, S. Tolaney, E. Winer · Cleveland Clinic
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  16. Abstract 42142026-06-02 · 20:15 CT · S100A
    ASCENT-760: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    M. Krop, S. Tolaney, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 12022026-06-04 · 15:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-1 study)
    F. Andre, M. Reck · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 10732026-06-01 · 16:30 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    T. Mok, G. Curigliano, C. Saura, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 45102026-06-02 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    H. Borghaei, J. Cortes, R. Herbst, et al. · Cleveland Clinic
    Education SessionGastrointestinal Cancer📄🖼️
  20. Abstract 91402026-06-05 · 18:00 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-722 study)
    P. Schmid, M. Reck, C. Robert, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 14192026-06-04 · 15:15 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-289
    A. Spira, G. Curigliano, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 11612026-06-05 · 16:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-73 study)
    E. Winer, T. Mok · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 13002026-06-05 · 21:30 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    L. Paz-Ares, A. Spira, C. Robert, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 60882026-06-03 · 20:15 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    H. Borghaei, S. Antonia, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  25. Abstract 13152026-06-03 · 14:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-627
    T. Mok, C. Saura, M. Krop, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 44192026-06-01 · 20:00 CT · E450
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-813 study)
    M.C. Garassino, P. Schmid, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  27. Abstract 98242026-06-01 · 21:30 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-474 study)
    C. Saura, J. Cortes · Institut Gustave Roussy
    Education SessionMelanoma📄🖼️
  28. Abstract 95972026-06-03 · 16:00 CT · S100A
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-294
    A. Spira, P. Schmid, H. Borghaei · Massachusetts General Hospital
    Education SessionMelanoma📄🖼️
  29. Abstract 97502026-06-03 · 13:00 CT · E450
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Tolaney, J. Cortes, S. Modi, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Small Cell📄🖼️
  30. Abstract 41022026-06-04 · 20:30 CT · Hall B1
    ASCENT-502: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    E. Winer, N. Rizvi, S. Modi, et al. · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 98902026-06-02 · 16:00 CT · Arie Crown Theater
    PACIFIC-722: Imfinzi (durvalumab) neoadjuvant in SCLC
    A. Spira, L. Paz-Ares, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 46092026-06-03 · 14:15 CT · S100A
    ASCENT-685: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    J. Cortes, T. Mok, J. Brahmer, et al. · Institut Gustave Roussy
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 18182026-06-03 · 14:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-454
    C. Robert, S. Antonia · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 97042026-06-05 · 14:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-947
    M. Reck, L. Paz-Ares, E. Winer · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 59412026-06-03 · 20:00 CT · S406
    Long-term follow-up of Lynparza 3L+ for ovarian: OlympiA-238
    H. Borghaei, C. Robert, N. Rizvi · University of Chicago
    Education SessionGynecologic Cancer📄🖼️
  36. Abstract 41202026-06-04 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    S. Antonia, H. Rugo, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Education SessionGastrointestinal Cancer📄🖼️
  37. Abstract 94412026-06-03 · 20:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-314
    S. Antonia, S. Peters, F. Andre, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 11172026-06-01 · 13:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-736 study)
    C. Robert, C. Saura, N. Rizvi, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 16142026-06-03 · 21:15 CT · E450
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-10
    S. Antonia, L. Paz-Ares, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 99842026-06-03 · 20:45 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-725
    N. Rizvi, E. Winer, H. Rugo · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 40932026-06-02 · 19:00 CT · S406
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-157
    M.C. Garassino, T. Mok, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 94122026-06-02 · 19:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-668
    S. Tolaney, N. Rizvi, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 98832026-06-05 · 15:15 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    N. Rizvi, M.C. Garassino, C. Saura · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 19242026-06-01 · 15:00 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-889
    S. Peters, M.C. Garassino, M. Reck · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 10412026-06-04 · 14:30 CT · S406
    MONALEESA-766: Kisqali (ribociclib) maintenance in HR+ breast cancer
    R. Herbst, S. Antonia · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 14612026-06-01 · 21:45 CT · E450
    KEYNOTE-981: Keytruda (pembrolizumab) 3L+ in TNBC
    J. Cortes, R. Herbst, C. Robert · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 93142026-06-02 · 20:30 CT · Hall B1
    IMpower-459: Tecentriq (atezolizumab) maintenance in NSCLC
    L. Paz-Ares, G. Curigliano, F. Andre, et al. · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 17372026-06-05 · 15:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-526
    E. Winer, J. Cortes, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 45842026-06-01 · 13:30 CT · Hall B1
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-73
    C. Robert, G. Curigliano, H. Borghaei, et al. · Institut Gustave Roussy
    Education SessionGastrointestinal Cancer📄🖼️
  50. Abstract 44852026-06-04 · 20:30 CT · S100A
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-494 study)
    C. Saura, E. Winer, F. Andre · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 45432026-06-04 · 18:45 CT · Hall B1
    EV-483: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    N. Rizvi, S. Antonia, A. Spira · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 15232026-06-01 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-71 study)
    E. Winer, H. Rugo, T. Mok · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 95112026-06-01 · 21:15 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-840 study)
    A. Spira, S. Peters, F. Andre, et al. · Mayo Clinic
    Education SessionMelanoma📄🖼️
  54. Abstract 63332026-06-01 · 13:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-859
    C. Robert, J. Cortes, S. Tolaney, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 45942026-06-01 · 13:30 CT · S406
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-759
    S. Antonia, H. Rugo, M. Reck, et al. · National Cancer Center Japan
    Education SessionGastrointestinal Cancer📄🖼️
  56. Abstract 43512026-06-02 · 13:15 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in gastric
    L. Paz-Ares, H. Rugo, C. Robert · Johns Hopkins Kimmel Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  57. Abstract 96802026-06-01 · 20:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-837
    C. Saura, H. Rugo, S. Modi, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 15912026-06-02 · 15:45 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    C. Saura, G. Curigliano, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 91062026-06-05 · 18:15 CT · S406
    FLAURA-478: Tagrisso (osimertinib) 3L+ in NSCLC
    H. Borghaei, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 41922026-06-05 · 19:00 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-963
    L. Paz-Ares, A. Spira · Princess Margaret Cancer Centre
    Education SessionGastrointestinal Cancer📄🖼️
  61. Abstract 47632026-06-02 · 18:30 CT · E450
    CheckMate-524: Opdivo (nivolumab) maintenance in HCC
    E. Winer, S. Tolaney · MD Anderson Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  62. Abstract 46922026-06-05 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-657 study)
    C. Robert, N. Rizvi, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 17382026-06-01 · 13:15 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Antonia, S. Peters, L. Paz-Ares · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 97372026-06-01 · 21:00 CT · Hall B1
    KEYNOTE-463: Keytruda (pembrolizumab) 2L in metastatic melanoma
    A. Spira, S. Tolaney, N. Rizvi, et al. · Cleveland Clinic
    Education SessionMelanoma📄🖼️
  65. Abstract 43692026-06-05 · 15:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-866 study)
    A. Spira, E. Winer, N. Rizvi, et al. · Karolinska Institute
    Education SessionGastrointestinal Cancer📄🖼️
  66. Abstract 18342026-06-05 · 19:45 CT · S406
    OlympiA-462: Lynparza (olaparib) 1L in HR+ breast cancer
    T. Mok, P. Schmid · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 98172026-06-02 · 13:30 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    P. Schmid, L. Paz-Ares, F. Andre · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 97452026-06-04 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-163
    S. Modi, T. Mok, E. Winer, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 42352026-06-03 · 21:15 CT · S406
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    C. Saura, J. Cortes, J. Brahmer, et al. · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  70. Abstract 104412026-06-04 · 13:00 CT · S406
    KEYNOTE-984: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Modi, E. Winer, H. Borghaei · Massachusetts General Hospital
    Education SessionMelanoma📄🖼️
  71. Abstract 100272026-06-05 · 16:45 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-260
    S. Antonia, M.C. Garassino, S. Tolaney · Massachusetts General Hospital
    Education SessionMelanoma📄🖼️
  72. Abstract 97872026-06-05 · 21:15 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    E. Winer, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 15082026-06-04 · 13:00 CT · S406
    MONALEESA-970: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    G. Curigliano, M.C. Garassino · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 16682026-06-05 · 20:15 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    C. Saura, H. Borghaei, M. Krop · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 64992026-06-02 · 16:30 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in RCC
    H. Rugo, S. Peters, P. Schmid, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  76. Abstract 45282026-06-03 · 15:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-658
    C. Saura, S. Peters, C. Robert · Vall d'Hebron Institute of Oncology
    Education SessionGastrointestinal Cancer📄🖼️
  77. Abstract 18582026-06-05 · 14:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-692
    S. Modi, H. Rugo, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 102772026-06-04 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    A. Spira, E. Winer, N. Rizvi · University of Chicago
    Education SessionMelanoma📄🖼️
  79. Abstract 11032026-06-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-347 study)
    H. Rugo, M. Krop, S. Modi · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 43022026-06-01 · 21:15 CT · S406
    EV-289: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    M.C. Garassino, N. Rizvi, C. Saura, et al. · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  81. Abstract 42562026-06-02 · 19:45 CT · S406
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-378
    H. Rugo, E. Winer, C. Robert · Karolinska Institute
    Education SessionGastrointestinal Cancer📄🖼️
  82. Abstract 44722026-06-03 · 16:45 CT · E450
    DESTINY-Breast-526: Enhertu (trastuzumab deruxtecan) 3L+ in gastric
    R. Herbst, J. Brahmer, S. Tolaney, et al. · Stanford Cancer Institute
    Education SessionGastrointestinal Cancer📄🖼️
  83. Abstract 65652026-06-03 · 20:45 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    S. Peters, R. Herbst, C. Robert, et al. · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  84. Abstract 17152026-06-03 · 18:30 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    L. Paz-Ares, H. Rugo · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 55532026-06-02 · 14:00 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in prostate
    P. Schmid, G. Curigliano, H. Borghaei, et al. · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Prostate📄🖼️
  86. Abstract 44452026-06-01 · 19:45 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    H. Borghaei, C. Saura, F. Andre · Memorial Sloan Kettering Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  87. Abstract 19352026-06-02 · 16:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-399
    S. Tolaney, S. Modi · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 94652026-06-03 · 16:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-670
    M. Reck, S. Peters, P. Schmid, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 96252026-06-05 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-146 study)
    S. Tolaney, E. Winer, C. Saura · MD Anderson Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 12312026-06-03 · 19:00 CT · E450
    MONARCH-186: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Peters, M. Reck, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 96062026-06-04 · 18:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-864 study)
    T. Mok, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 42042026-06-04 · 15:15 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-426 study)
    E. Winer, M. Reck · Chinese University of Hong Kong
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  93. Abstract 97442026-06-01 · 14:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-233
    S. Antonia, G. Curigliano, S. Modi · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 16872026-06-03 · 20:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-54
    S. Antonia, J. Cortes · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 42862026-06-05 · 13:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in HCC
    S. Antonia, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  96. Abstract 48612026-06-04 · 15:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-360 study)
    C. Saura, M.C. Garassino, A. Spira · Institut Gustave Roussy
    Education SessionGastrointestinal Cancer📄🖼️
  97. Abstract 14782026-06-05 · 19:45 CT · S406
    MONARCH-292: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    S. Tolaney, J. Brahmer · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 47912026-06-01 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-557
    R. Herbst, M. Krop · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 14142026-06-02 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-524 study)
    F. Andre, A. Spira · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 97802026-06-05 · 21:30 CT · Arie Crown Theater
    KEYNOTE-252: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    S. Tolaney, E. Winer, H. Borghaei, et al. · MD Anderson Cancer Center
    Education SessionMelanoma📄🖼️
  101. Abstract 41312026-06-03 · 18:15 CT · S406
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-318
    M.C. Garassino, N. Rizvi, S. Peters, et al. · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 17772026-06-04 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-777 study)
    J. Brahmer, M.C. Garassino, R. Herbst, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 61322026-06-02 · 19:00 CT · E450
    Quality of life outcomes with Lynparza in patients with ovarian
    N. Rizvi, S. Peters, L. Paz-Ares · University of Chicago
    Education SessionGynecologic Cancer📄🖼️
  104. Abstract 95332026-06-02 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-626
    J. Cortes, H. Rugo, M. Reck · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 16942026-06-05 · 16:45 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    E. Winer, H. Borghaei · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 99592026-06-05 · 18:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Rugo, E. Winer, S. Tolaney, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  107. Abstract 14832026-06-02 · 16:30 CT · E450
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-789
    A. Spira, R. Herbst, M. Krop · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 90252026-06-04 · 20:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-821 study)
    S. Modi, P. Schmid, A. Spira, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 57632026-06-02 · 15:00 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    H. Borghaei, P. Schmid · Chinese University of Hong Kong
    Education SessionGynecologic Cancer📄🖼️
  110. Abstract 15872026-06-04 · 16:15 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-639 study)
    E. Winer, S. Tolaney, S. Peters · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 99852026-06-01 · 21:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-841
    T. Mok, J. Cortes · University of Chicago
    Education SessionLung Cancer—Small Cell📄🖼️
  112. Abstract 97632026-06-04 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-990
    S. Tolaney, M.C. Garassino, S. Modi, et al. · MD Anderson Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 91842026-06-03 · 18:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    H. Borghaei, S. Peters, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 94952026-06-04 · 14:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-422
    J. Brahmer, M. Reck, G. Curigliano, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 58982026-06-03 · 20:00 CT · E450
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-719
    H. Borghaei, A. Spira, G. Curigliano, et al. · Mayo Clinic
    Education SessionGynecologic Cancer📄🖼️
  116. Abstract 99742026-06-04 · 19:30 CT · Hall B1
    PACIFIC-80: Imfinzi (durvalumab) 3L+ in NSCLC
    S. Antonia, C. Robert · MD Anderson Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 15612026-06-01 · 19:30 CT · S406
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-398
    J. Brahmer, R. Herbst · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 43562026-06-02 · 21:15 CT · Hall B1
    ASCENT-677: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    H. Rugo, E. Winer, S. Modi, et al. · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  119. Abstract 97262026-06-05 · 19:45 CT · E450
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-474
    S. Antonia, M. Krop, E. Winer · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract 12692026-06-02 · 15:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-227
    S. Antonia, S. Peters, C. Saura, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 11712026-06-01 · 21:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-233 study)
    J. Cortes, M.C. Garassino, S. Antonia, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 66872026-06-01 · 18:00 CT · S406
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-956
    H. Borghaei, C. Saura, J. Cortes · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 12072026-06-03 · 13:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-282
    G. Curigliano, S. Peters, F. Andre, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 17482026-06-02 · 21:30 CT · S406
    DESTINY-Breast-778: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    E. Winer, N. Rizvi, C. Saura, et al. · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 14052026-06-05 · 15:45 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-709
    R. Herbst, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 98332026-06-03 · 13:45 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    E. Winer, G. Curigliano, J. Brahmer, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 94462026-06-04 · 16:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-789
    C. Saura, F. Andre · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  128. Abstract 57922026-06-05 · 21:15 CT · E450
    OlympiA-383: Lynparza (olaparib) 1L in ovarian
    F. Andre, J. Brahmer, M. Reck, et al. · University of Chicago
    Education SessionGynecologic Cancer📄🖼️
  129. Abstract 16732026-06-02 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-502 study)
    L. Paz-Ares, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 42522026-06-02 · 14:30 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for HCC: IMpower-452
    C. Saura, N. Rizvi, S. Antonia · Dana-Farber Cancer Institute
    Education SessionGastrointestinal Cancer📄🖼️
  131. Abstract 98992026-06-01 · 19:15 CT · Hall B1
    DESTINY-Breast-745: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    C. Robert, G. Curigliano, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 19072026-06-01 · 13:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-59 study)
    C. Saura, M. Reck · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 16002026-06-04 · 13:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-346 study)
    M. Reck, T. Mok, C. Saura · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 98142026-06-05 · 21:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-742 study)
    C. Saura, H. Rugo, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 90442026-06-04 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-972
    M. Krop, F. Andre, L. Paz-Ares, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 19142026-06-01 · 15:00 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-19
    E. Winer, H. Borghaei, J. Brahmer, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 43082026-06-03 · 14:15 CT · Arie Crown Theater
    EV-307: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    T. Mok, R. Herbst, A. Spira, et al. · Peter MacCallum Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.